# Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

> **NCT05703971** · PHASE1,PHASE2 · RECRUITING · sponsor: **Genprex, Inc.** · enrollment: 62 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **BIOLOGICAL:** quaratusugene ozeplasmid
- **BIOLOGICAL:** atezolizumab

## Key facts

- **NCT ID:** NCT05703971
- **Lead sponsor:** Genprex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-09
- **Primary completion:** 2026-02
- **Final completion:** 2027-08
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05703971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05703971, "Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05703971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*